SVB Securities analyst Jonathan Chang reiterated a Buy rating on Vincerx Pharma Inc (VINC – Research Report) on May 11 and set a price target of $5.00. The company’s shares closed last Friday at $1.63.
Chang covers the Healthcare sector, focusing on stocks such as Kura Oncology, Revolution Medicines, and ImmunoGen. According to TipRanks, Chang has an average return of -9.1% and a 33.95% success rate on recommended stocks.
Currently, the analyst consensus on Vincerx Pharma Inc is a Moderate Buy with an average price target of $5.00.
See the top stocks recommended by analysts >>
Based on Vincerx Pharma Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $150 billion and a GAAP net loss of $14.34 million. In comparison, last year the company had a GAAP net loss of $16.42 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LifeSci Acquisition Corp is a blank check company.
Read More on VINC:
- Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Vincerx Pharma presents preclinical data on VIP924
- Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023
- Vincerx Pharma presents preclinical data on SMDCs at AACR
